Evidence map›Paper›PMID 26312219›Full record

ReviewGland surgery2015

Parathyroid cancer.

Fiona McClenaghan, Yassar A Qureshi

Abstract readReview
In one paragraph

Review in Gland surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Parathyroid Carcinoma: a Review.Indian journal of surgical oncology · 2022
    Review
  6. Article
  7. Article
  8. Journal of the Endocrine Society · 2019
    Article
  9. Surgical Treatment for Parathyroid Adenoma: A Case Report.Open access Macedonian journal of medical sciences · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Atypical manifestation of parathyroid carcinoma with late-onset distant metastases.Endocrinology, diabetes & metabolism case reports · 2017
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fiona McClenaghanDepartment of Surgery, the Royal London Hospital, London, UK.
Yassar A QureshiDepartment of Surgery, the Royal London Hospital, London, UK.
Royal London Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parathyroid carcinoma is an exceedingly rare endocrine malignancy first described in 1933. It accounts for between 0.5% and 5% of all cases of primary hyperparathyroidism. Parathyroid carcinoma is unusual among endocrine malignancies, being more hormonally active than its benign counterpart. Parathyroid carcinoma poses a diagnostic challenge both clinically and histologically due to the lack of features which can definitively distinguish malignant from benign disease early in its clinical course. Here, we describe the clinical features of the disease, and present the current opinion on optimal management. Further, we analyse the most recent histological advances made to aid in the diagnosis and management of this rare, but potentially devastating, disease.

Indexed as

endocrine malignancyparathyroid cancerParathyroid glandprimary hyperparathyroidism

Identifiers

PMID26312219
PMCPMC4523631
OpenAlexW4292579787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.